The follow-on investment in Helix's $200 million Series B round furthers Mayo’s goal to ‘democratize’ patient knowledge.
Two investors who collectively own 60 percent of Cogentix Medical have already approved the deal's terms.
The biopharmaceutical company plans to use the money to fund a new round of human trial testing.
Massachusetts-based Hologic Inc. landed the U.S. rights for the University of Minnesota's 'Dexalytics' athletic performance software.
The deal, which largely involves Surmodics' SurVeil drug-coated balloon, would give Abbott worldwide commercialization rights once the device receives FDA approval.
The mixed public-private effort with Vaccinex is aiming to bring about a treatment for intractable osteosarcoma.
Sonex Health of Rochester and Oculogics of Minneapolis land initial venture backing.
Fast Company highlighted the Minneapolis medical startup on its Top 50 list.
The company is currently developing a drug for market approval that treats lower back pain.